Anti-R-Hirudin Antibodies Reveal Clinical Relevance through Direct Functional Inactivation of R-Hirudin or Prolongation of R-Hirudin’s Plasma Halflife

• References

• 1 Huhle G, Hoffmann U, Song X, Wang LC, Heene DL, Harenberg J. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 1999; 106: 195-201.
• 2 Song XH, Huhle G, Wang LC, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies inheparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999; 100: 1528-32.
• 3 Rehlaender BN, Cho MJ. Antibodies as carrier proteins. Pharm Res 1998; 15: 1652-6.
• 4 Markwardt F, Fink G, Kaiser B, Klocking HP, Nowak G, Richter M, Stürzebecher J. Pharmacological survey of recombinant hirudin. Pharmazie 1988; 43: 202-7.
• 5 Gygax D, Botta L, Ehrat M, Graf P, Lefevre G, Orszalan P, Pfister C. Immunoassays in monitoring biotechnological drugs. Ther Drug Monit 1996; 18: 405-9.
• 6 Koch C, Whitechurch O, Cordier P, Roitsch C. Anti-hirudin monoclonal antibodies directed toward discontinuous epitopes of the hirudin amino terminal and epitopes involving the carboxy-terminal hirudin amino acids. AnalytBiochem 1993; 214: 301-12.
• 7 Friguet B, Chaffotte AF, Djavadi-Ohaniance Goldberg ME. Measurement of the true affinity constant in solution of antigen antibody complexes by enzyme-linked immunosorbent assay. J Immunol Meth 1985; 77: 305-19.
• 8 Nowak G, and Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996; 22: 197-202.
• 9 Griessbach U, Stürzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res 1985; 37: 347-50.